title: Clinical review of the newer intravenous iron therapy options.
abstract: The effectiveness of iron sucrose was recently evaluated in several small groups of hemodialysis patients in five regional dialysis units. Iron sucrose did not maintain hemoglobin levels above 11 g/dl and transferrin saturation above 25%. In addition, close to 50% of the patients experienced serum ferritin levels greater than 1100 ng/ml, suggesting iron overload. Consequently, iron therapy was withheld in these patients. Eventually, several patients experienced a decrease in ferritin levels to below 800 ng/ml and were administered iron therapy with sodium ferric gluconate instead of iron sucrose. These patients achieved hemoglobin levels greater than 11 g/dl, and serum ferritin levels remained within the target range after several months of treatment.
authors.affiliation: Gambro Healthcare Patient Services, Inc., Charlotte, NC, USA.
authors.forename: Jo H
authors.initials: JH
authors.lastname: Edwards
mesh_terms: D018798:Anemia, Iron-Deficiency / Q000188:drug therapy*; D002985:Clinical Protocols; D005290:Ferric Compounds / Q000008:administration & dosage* / Q000097:blood*; D000077605:Ferric Oxide, Saccharated; D005293:Ferritins / Q000097:blood; D005937:Glucaric Acid; D006454:Hemoglobins / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D006435:Renal Dialysis / Q000009:adverse effects; D014168:Transferrin / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D005290:Ferric Compounds; D006454:Hemoglobins; D014168:Transferrin; D005293:Ferritins; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid